Current Oncology Reports

, Volume 4, Issue 1, pp 9–19 | Cite as

Tyrosine kinase inhibitors: A clinical perspective

  • Sanjay Goel
  • Sridhar Mani
  • Roman Perez-Soler
Article

Abstract

Cancer treatment has so far been restricted to cytotoxic and hormonal agents. These have been of limited value in their efficacy and their toxicity profile. A new era of targeted therapies is rapidly evolving. A key target being actively pursued is the receptor tyrosine kinase. Several compounds that inhibit this target are in preclinical and clinical development. These compounds broadly fall into two categories: monoclonal antibodies and small-molecule inhibitors. The common targets are epidermal growth factor receptor, Bcr-Abl tyrosine kinase, vascular endothelial growth factor, fibroblast growth factor receptor, and platelet-derived growth factor. Two of these compounds, trastuzumab and imatinib mesylate, have been approved by the US Food and Drug Administration for use in specific indications. Other uses are being tested, such as iImatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70. This paper reviews the broad principles and knowledge about cancer. It highlights principles of growth control and development of targeted therapy.PubMedCrossRefGoogle Scholar
  2. 2.
    Stehelin D, Varmus HE, Bishop JM, et al.: DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976, 260:170–173.PubMedCrossRefGoogle Scholar
  3. 3.
    Hill CS, Treisman R: Transcription regulation by extracellular signals: mechanisms and specificity. Cell 1995, 80:199–211.PubMedCrossRefGoogle Scholar
  4. 4.
    Fedi P, Tronick SR, Aaronson SA: Growth factors. In Cancer Medicine. Edited by Holland JF, Bast RC, Morton DL, et al. Baltimore, MD: Williams & Wilkins; 1997:41–64.Google Scholar
  5. 5.
    Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999, 285:1028–1032.PubMedCrossRefGoogle Scholar
  6. 6.
    Hunter T, Cooper JA: Protein-tyrosine kinases. Annu Rev Biochem 1985, 54:897–930.PubMedGoogle Scholar
  7. 7.
    Porter AC, Vaillancourt RR: Tyrosine kinase receptor-activated signal tranduction pathways which lead to oncogenesis. Oncogene 1998, 17:1343–1352.PubMedCrossRefGoogle Scholar
  8. 8.
    Hubbard SR, Hill JH: Protein tyrosine kinase structure and function. Annu Rev Biochem 2000, 69:373–398.PubMedCrossRefGoogle Scholar
  9. 9.
    Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203–212.PubMedCrossRefGoogle Scholar
  10. 10.
    Fantl WJ, Johnson DE, Willims LT: Signaling by receptor tyrosine kinases. Annu Rev Biochem 1993, 62:453–481.PubMedGoogle Scholar
  11. 11.
    Tonks NK, Neel BG: From form to function: signaling by protein tyrosine phosphatases. Cell 1996, 87:365–368.PubMedCrossRefGoogle Scholar
  12. 12.
    Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213–223.PubMedCrossRefGoogle Scholar
  13. 13.
    Neet K, Hunter T: Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996, 1:147–169.PubMedCrossRefGoogle Scholar
  14. 14.
    Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors. Cell 1994, 76:263–274.PubMedCrossRefGoogle Scholar
  15. 15.
    Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995, 129:895–898.PubMedCrossRefGoogle Scholar
  16. 16.
    Bacus SS, Zenick CR, Plowman G, et al.: Expression of the erbB-2 family of growth factors and their ligands in breast cancers: implication for tumor biology and clinical behavior. Am J Clin Pathol 1994, 102(suppl 1):S13-S24.PubMedGoogle Scholar
  17. 17.
    Ben-Bassat H, Rosenbaum-Mitrani S, Hartzsark Z, et al.: Inhibition of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of HPV 16 immortalized human keratinocytes. Cancer Res 1997, 57:3741–3750.PubMedGoogle Scholar
  18. 18.
    Yoneda T, Lyall RM, Alisina MM, et al.: The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 1991, 51:4430–4435.PubMedGoogle Scholar
  19. 19.
    Nagane M, Levitzki A, Gazit A, et al.: Drug resistance of human glioblastoma cells conferred by a tumor specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspace—3 like proteases. Proc Natl Acad Sci U S A 1998, 95:5724–5729.PubMedCrossRefGoogle Scholar
  20. 20.
    Posner I, Engel M, Levitzki A: Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF. J Biol Chem 1992, 267:20638–20647.PubMedGoogle Scholar
  21. 21.
    Fan Z, Mendelsohn J: Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol 1998, 10:67–73.PubMedGoogle Scholar
  22. 22.
    Yaish P, Gazit A, Gilon C, et al.: Blocking of EGF-dependent cell proliferation by EGFR kinase inhibitors. Science 1988, 242:933–935.PubMedCrossRefGoogle Scholar
  23. 23.
    Levitzki A, Bohmer FD: Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases. Anticancer Drug Des 1998, 13:731–734.PubMedGoogle Scholar
  24. 24.
    Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037. This report provides the first demonstration of the amazing success of imatinib mesylate for treating chronic myeloid leukemia and its excellent efficacy profile. The dose for future trials was suggested as 400 mg; of note, this suggestion was not based on the toxicity profile.PubMedCrossRefGoogle Scholar
  25. 25.
    Druker BJ, Sawyers GL, Kantarjian H, et al.: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042. Blast crisis in CML has traditionally been the end stage of this otherwise chronic disease. The demonstration that imatinib could salvage some of these patients offers some hope for clinicians.PubMedCrossRefGoogle Scholar
  26. 26.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056. It has been shown that imatinib not only inhibits the Bcr-Abl tyrosine kinase but also the SCF c-kit and may have therapeutic value in the treatment of gastrointestinal stromal tumor, an otherwise untreatable disease. This paper profiles a patient who clinically responded to this medication.PubMedCrossRefGoogle Scholar
  27. 27.
    Blanke CD, von Mehren M, Joensuu H, et al.: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) expressing c-kit (CD117) [abstract]. Proc ASCO 2001, 20:1a.Google Scholar
  28. 28.
    Van OosteromAT, Judson I, Verweij J, et al.: STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST). An EORTC phase I study [abstract]. Proc ASCO 2001, 20:1a.Google Scholar
  29. 29.
    Sjoblom T, Shimizu A, O’Brien KP, et al.: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001, 61:5778–5783.PubMedGoogle Scholar
  30. 30.
    Pegram M, Slamon D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000, 27(suppl 9):13–19.PubMedGoogle Scholar
  31. 31.
    Drebin JA, Link VC, Stern DF, et al.: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41:697–706.PubMedCrossRefGoogle Scholar
  32. 32.
    Cooley S, Burns LJ, Repka T, et al.: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999, 27:1533–1541.PubMedCrossRefGoogle Scholar
  33. 33.
    Baselga J, Tripathy D, Mendelson J, et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737–744.PubMedGoogle Scholar
  34. 34.
    Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639–2648.PubMedGoogle Scholar
  35. 35.
    Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792. This study demonstrated the role of monoclonal antibodies for treating metastatic breast cancer; response rates were increased, and survival was prolonged. This drug had unexpected cardiac toxicity in the ejection fraction of the treated patients.PubMedCrossRefGoogle Scholar
  36. 36.
    Seidman AD, Fornier MN, Esteva FJ, et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001, 19:2587–2595. This pivotal study showed a survival benefit for combination therapy with paclitaxel and trastuzumab in patients with metastatic breast cancer whose tumors overexpressed the HER2 receptor. The detected level of receptor expression depended on the type of assay used, and this led to variation in the survival benefit based on receptor expression.PubMedGoogle Scholar
  37. 37.
    Kalemkerian GP: Growth factors. In Lung Cancer: Principles and Practice. Edited by Pass HI, Mitchell JB, Johnson DH, et al. Philadelphia: Lippincott Williams & Wilkins; 2000:181–198.Google Scholar
  38. 38.
    You XL, Yen L, Zeng-Rong N, et al.: Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. Oncogene 1998, 17:3177–3186.PubMedCrossRefGoogle Scholar
  39. 39.
    Pegram MD, Finn RS, Arzoo K, et al.: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997, 15:537–547.PubMedCrossRefGoogle Scholar
  40. 40.
    Kern JA, Torney L, Weiner D, et al.: Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Respir Cell Mol Biol 1993, 9:448–454.PubMedGoogle Scholar
  41. 41.
    Krug LM, Miller VA, Crapanzano J, et al.: Randomized phase II trial of trastuzumab plus either weekly docetaxel or paclitaxel in previously untreated advanced non-small cell lung cancer [abstract]. Proc ASCO 2001, 20:333a.Google Scholar
  42. 42.
    Meden H, Beneke A, Hesse T, et al.: Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 2001, 21:1301–1305.PubMedGoogle Scholar
  43. 43.
    Burstein HJ, Kuter I, Campos SM, et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001, 19:2722–2730.PubMedGoogle Scholar
  44. 44.
    Woodburn J: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82:241–250.PubMedCrossRefGoogle Scholar
  45. 45.
    Ciardiello F, Caputo R, Bianco R, et al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res 2001, 7:1459–1465.PubMedGoogle Scholar
  46. 46.
    Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053–2063.PubMedGoogle Scholar
  47. 47.
    Sirotnak FM, Zakowski MF, Miller VA, et al.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Canc Res 2000, 6:4885–4892.Google Scholar
  48. 48.
    Chan KC, Knox WF, Gandhi A, et al.: Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 2001, 88:412–418.PubMedCrossRefGoogle Scholar
  49. 49.
    Smaill JB, Rewcastle GW, Loo JA, et al.: Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido. J Med Chem 2000, 43:1380–1397.PubMedCrossRefGoogle Scholar
  50. 50.
    Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Rad Oncol Biol Phys 2000, 48:1519–1528.CrossRefGoogle Scholar
  51. 51.
    Nelson JM, Fry DW: Akt, MAPK (Erk 1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001, 276:14842–14847.PubMedCrossRefGoogle Scholar
  52. 52.
    Sato N, Beitz JG, Kato J, et al.: Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993, 142:1119–1130.PubMedGoogle Scholar
  53. 53.
    Eckhardt SG, Rizzo J, Sweeney KR, et al.: Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol 1999, 17:1095–1104.PubMedGoogle Scholar
  54. 54.
    Laird AD, Vajkoczy P, Shawver LK, et al.: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000, 60:4152–4160.PubMedGoogle Scholar
  55. 55.
    Smolich BD, Yuen HA, West KA, et al.: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001, 97:1413–1421.PubMedCrossRefGoogle Scholar
  56. 56.
    Batley BL, Doherty AM, Hamby JM, et al.: Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci 1998, 62:143–150.PubMedCrossRefGoogle Scholar
  57. 57.
    Panek RL, Lu GH, Klutchko SR, et al.: In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharm Exp Ther 1997, 283:1433–1444.Google Scholar
  58. 58.
    Fujimoto J, Hori M, Ichigo S, et al.: Plausible novel therapeutic strategy of uterine endometial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470). Cancer Lett 1997, 113:187–194.PubMedCrossRefGoogle Scholar
  59. 59.
    Sirica AE, Lai GH, Zhang Z: Biliary cancer growth factor pathways, cylco-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 2001, 16:363–372.PubMedCrossRefGoogle Scholar
  60. 60.
    Mani S, Gu Y, Wadler S, et al.: Antisense therapeutics in oncology: points to consider in their clinical evaluation. Antisense Nucleic Acid Drug Devel 1999, 9:543–547.Google Scholar
  61. 61.
    Brugge JS, McCormick F: Cell regulation: intracellular networking. Curr Opin Cell Biol 1999, 11:173–176.CrossRefGoogle Scholar
  62. 62.
    Mass RD, Sanders C, Charlene K, et al.: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials [abstract]. Proc ASCO 2000, 19:75a. The authors highlight the concept of the variation between viability of receptors and the physical number of receptors and enable the reader to conceptualize the distinction between maximum tolerated dose and optimal biologic dose.Google Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Sanjay Goel
    • 1
  • Sridhar Mani
    • 1
  • Roman Perez-Soler
    • 1
  1. 1.Division of OncologyMontefiore Medical CenterBronxUSA

Personalised recommendations